Customized Specimen Collection Kits Provide Convenience, Accuracy and Promotion Ideal for Post-Marketing Studies
Rochester, NY, Sept. 22, 2008 – ACM-Pivotal <http://www.acm-pivotal.com/> , the global central laboratory that continually defines the customer-service standard with its flexible approach, is now offering its unique KitKaddySM and lab collection kits to pharmaceutical, biotech and contract research organizations (CROs) that want to promote their brand at the physician level. The environmentally-friendly diagnostic specimen kits have been designed as easy-to-use space savers that help standardize collection across sites and countries. Companies can provide their logo, colors and additional brand elements to be printed on the kits, which will be housed at investigator sites throughout a clinical trial.
ACM-Pivotal will be showcasing its KitKaddy and collection kits, along with its safety testing expertise, at the 11th Registries and Post Approval Studies Congress <http://www.acm-pivotal.com/Registries_contact.html> in Washington, DC Sept. 23-25. The conference agenda is aimed at post-approval studies for improved safety and risk assessment.
ACM-Pivotal has been shipping KitKaddy and lab collection kits to investigator sites globally since 2003 and has received positive response from both investigators and sponsors. Customer demand and increased post-marketing studies have prompted ACM-Pivotal to offer a white-labeled solution to help increase brand awareness of new drugs available on the market.
“Our KitKaddy and lab collection kits are now multipurpose. Not only are they ideal for large safety studies, they provide an additional avenue for sponsors to reinforce their brands to a key audience,” said Elena Logan, VP, Clinical Trials. “With the continued emphasis on post-marketing safety studies, we are pleased to have a solution that is very well aligned with these commitments.”
The KitKaddy is organized with 24 custom visit and protocol-specific laboratory supply trays with the capacity to support large safety studies. Designed specifically for each clinical trial, all the necessary draw supplies are included. ACM-Pivotal’s collection kits enable clinicians to easily adhere to the specimen collection portion of protocols. Furthermore, the kits are assembled in a facility using 100 percent wind energy and manufactured using paperboard that is 100 percent recyclable and made from a renewable resource. The high-quality kits are produced in an ISO 9002 certified facility.
For more information and photos, please visit http://www.acm-pivotal.com/news_KitKaddy_9_22_08.html
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.